Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenip Plc Regulatory News (GNIP)

Share Price Information for Genip Plc (GNIP)

Share Price is delayed by 15 minutes
Get Live Data
4.65    0.00 (0.00%)
Bid:
4.50
Ask:
4.80
Spread: 0.30 (6.667%)
Market Cap: £1.19m
GNIP Live PriceLast checked at - London Stock Exchange

Intraday Genip Plc Share Chart

Result of AGM

26 Jun 2025 17:07

RNS Number : 6288O
GenIP PLC
26 June 2025
 

 

 

26 June 2025

GenIP Plc

("GenIP" or the "Company")

Result of AGM

 

GenIP Plc (AIM: GNIP), a technology business providing Generative Artificial Intelligence (GenAI) solutions to help research organisations and corporations commercialise their innovations, is pleased to announce that at the Company's Annual General Meeting ("AGM") held earlier today all resolutions were duly passed.

 

The number of votes cast for and against each of the resolutions proposed, and the number of votes withheld were as follows:

 

Resolution

For

%

Against

%

Votes withheld

Total votes cast

Ordinary Resolutions

(1) Approval of the Annual Report and Accounts

13,895,578

99.95

6,685

0.05

104,665

13,902,263

(2) Re-appoint HW Fisher LLP as auditor of the Company

13,895,578

99.95

6,685

0.05

104,665

13,902,263

(3) Authorise the Directors to determine the auditor's remuneration

13,895,578

99.95

6,685

0.05

104,665

13,902,263

(4) Re-elect Lord David Willetts as a director of the Company

13,767,373

99.03

134,890

0.97

104,665

13,902,263

(5) Re-elect Melissa Cruz as a director of the Company

13,767,373

99.03

134,890

0.97

104,665

13,902,263

(6) Re-elect Kevin Fitzpatrick as a director of the Company

13,895,578

99.95

6,685

0.05

104,665

13,902,263

(7) Re-elect Prof. David Gann CBE as a director of the Company

13,767,373

99.03

134,890

0.97

104,665

13,902,263

(8) To authorise the Directors to allot shares, up to an aggregate nominal amount of £37,224.61

13,759,681

99.03

134,890

0.97

112,357

13,894,571

Special Resolution

(9) To authorise the Directors to disapply pre-emption rights when issuing share, up to an aggregate nominal amount of £37,224.61

13,759,681

99.03

134,890

0.97

112,357

13,894,571

 

Notes:

1. Proxy appointments which gave discretion to the Chairman of the AGM have been included in the "For" total for the appropriate resolution.

2. Votes "For" and "Against" any resolution are expressed as a percentage of votes validly cast for that resolution.

3. A "Vote withheld" is not a vote in law and is not counted in the calculation of the percentage of shares voted "For" or "Against".

4. The full text of the resolutions passed at the AGM can be found in the Notice of Annual General Meeting which is available on the Company's website at http://genip.ai/results-presentations/.

 

As at 26 June 2025, there were 17,517,461 ordinary shares in issue. Shareholders are entitled to one vote per share.

 

Votes withheld are not votes in law and so have not been included in the calculation of the proportion of votes for and against a resolution.

 

Enquiries:

 

GenIP Plc

Melissa Cruz, CEO 

Via Redchurch Communications

Beaumont Cornish Limited (Nominated Adviser)

Roland Cornish / Asia Szusciak / Andrew Price

 

 

Tel: +44 (0) 20 7628 3396

 

Novum Securities Limited (Broker) 

Jon Belliss

Tel: +44 (0)20 7399 9425

JBelliss@novumsecurities.com

 

 

Redchurch Communications (Financial PR)

John Casey

 

 

genip@weareredchurch.com

 

Beaumont Cornish Limited ("Beaumont Cornish") is the Company's Nominated Adviser and is authorised and regulated by the FCA. Beaumont Cornish's responsibilities as the Company's Nominated Adviser, including a responsibility to advise and guide the Company on its responsibilities under the AIM Rules for Companies and AIM Rules for Nominated Advisers, are owed solely to the London Stock Exchange. Beaumont Cornish is not acting for and will not be responsible to any other persons for providing protections afforded to customers of Beaumont Cornish nor for advising them in relation to the proposed arrangements described in this announcement or any matter referred to in it.

About GenIP

 

GenIP provides generative artificial intelligence (GenAI) analytic services to help companies, research institutions and venture funds assess and commercialise new discoveries. GenIP combines expert human technical review with GenAI algorithms to provide insightful and verified services.

 

GenIP provides two complementary platform-based services:

 

1. Invention Evaluator: Provides bespoke research reports that assess the market potential of new technological innovations and discoveries using AI-driven proprietary software; and

 

2. Vortechs: which is an executive recruitment platform that through advanced machine learning algorithms and natural language processing technologies assists in matching technology organisations with experienced executives skilled in technology commercialisation.

 

The Company believes that its integrated GenAI service offerings will help organisations to evaluate and commercialise their technological innovations. 

 

Company Strategy

 

GenIP's goal is to be a leading Generative AI analytic services company. To achieve this, the Company has established three strategic pillars:

 

· Organically grow Invention Evaluator and Vortechs' revenue through institutional and corporate connections as well as increase client pipeline through marketing, advertising and social media spend.

 

· Expand the Generative AI service offerings within Invention Evaluator and Vortechs' to reach new customers and improve margins.

 

· Bolt-on acquisitions of additional Generative AI services that are helpful to our clients and have demonstrated initial market traction. 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGPKABBPBKDFAB
Date   Source Headline
30th Jun 20267:00 amRNS-RCorporate Update
24th Jun 20265:18 pmRNSResult of AGM
24th Jun 20267:00 amRNS-RGenIP Innovation Roundtable
29th May 20265:52 pmRNSTotal Voting Rights
27th May 20267:00 amRNSAudited Final Results FY25 and Notice of AGM
21st May 20267:00 amRNSNew Orders
5th May 202611:35 amRNSTR-1: Notification of major holdings
1st May 20267:00 amRNSShare Placing to raise £350,000 and TVR
28th Apr 20267:00 amRNSStrategic Resale Alliance with Cardinal IP
31st Mar 20267:00 amRNS-RCommercial Update
10th Feb 20267:00 amRNS-RSales and Product Update
15th Jan 20267:00 amRNSCorporate Update
4th Dec 20257:00 amRNSOperational Update, Placing and TVR
21st Nov 20257:00 amRNS-RNew Report Orders From Repeat Clients
13th Nov 20257:00 amRNSTrading Statement
15th Oct 20257:00 amRNS-RTechnology Park Alliance
10th Oct 20257:00 amRNSNew Product Launch – Invention Validator
6th Oct 20257:00 amRNSReplacement RNS: Half-year Report
30th Sep 20257:02 amRNSCommercial Strategy Update & New Products
30th Sep 20257:00 amRNSHalf-year Report
24th Sep 20257:00 amRNS-RStrategic Partnership
15th Sep 20257:00 amRNS-RStrategic Partnership
25th Jul 20257:00 amRNSTrading Statement
1st Jul 20257:00 amRNS-RGenIP Secures First UK Academic Clients
26th Jun 20255:07 pmRNSResult of AGM
10th Jun 20257:00 amRNSContract Win
4th Jun 20257:00 amRNSAudited Results for Period Ended 31 December 2024
2nd Jun 20256:27 pmRNSNotice of AGM
29th May 20257:00 amRNS-RBusiness Update
7th May 20257:00 amRNS-RGenIP to attend 2025 AUTM Canadian Region Meeting
1st May 20257:00 amRNS-RNew Product Launch
31st Mar 20255:34 pmRNSUnaudited Results to 31 December 2024
26th Mar 20257:00 amRNS-RContract Win
20th Mar 20257:00 amRNS$0.35m Contract Win
13th Mar 20257:00 amRNSCorporate Update & 2025 Outlook
11th Feb 20257:00 amRNS-RGenIP to Sponsor the AUTM 2025 Annual Meeting
3rd Dec 20245:29 pmRNSTR-1: Notification of major holdings
20th Nov 20247:00 amRNSCorporate Update
8th Oct 20247:00 amRNSCorporate Update
2nd Oct 20247:00 amRNSAdmission to Trading on AIM-First Day of Dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.